Church & Dwight
This article was originally published in The Rose Sheet
Executive Summary
Firm will pay approximately $254 mil. to purchase Kelso & Co.'s 50% interest in Armkel, with sale expected to close around May 30, Princeton, N.J. company announces May 6. Purchase is expected to have a negative impact on C&D's second and third quarter earnings, but likely will be accretive by early 2005, firm says. C&D acquired Armkel in a 50/50 joint venture with Kelso in 2001 (1"The Rose Sheet" May 14, 2001, p. 9). Firm predicts Q1 diluted net income per share will increase 40% to $.70 per share and revenue will rise 19% to $296 mil., boosted by a longer quarter and the recent acquisition of Unilever's North American oral care business. First quarter results will be announced May 11...
You may also be interested in...
Church & Dwight U.S. Personal Care Sales Near $500 Mil. With C-W Brands
Church & Dwight's U.S. personal care product sales will increase more than three-fold to nearly $500 mil. with the acquisition of the Carter-Wallace consumer brands. Revenues for Church & Dwight's personal products business currently total about $150 mil., according to the company.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.